<DOC>
	<DOCNO>NCT02760225</DOCNO>
	<brief_summary>This two center , single arm , investigator sponsor trial ( IST ) PET tracer 89Zr-pembrolizumab evaluate vivo whole body distribution 89Zr-Pembrolizumab registered indication : locally advance metastatic melanoma non-small cell lung cancer Pembrolizumab treatment .</brief_summary>
	<brief_title>Pembrolizumab-PET Imaging</brief_title>
	<detailed_description>Rationale : Immunotherapy target specific immune-regulatory checkpoint , mainly cytotoxic T-lymphocyte antigen-4 ( CTLA-4 ) Programmed Death ( PD1 ) PD ligand 1 ( PD-L1 ) show spectacular effect broad range solid malignancy , include melanoma non-small cell lung cancer ( NSCLC ) . Pembrolizumab , monoclonal antibody block interaction PD-1 T-cells ligands PD-L1 PD-L2 . Anti-tumor activity acceptable side effect profile show melanoma NSCLC . Radio-labeling pembrolizumab positron emission tomography ( PET ) radionuclide 89Zirkonium ( 89Zr ) enable serial non-invasive imaging quantification distribution PD-1 melanoma patient . By perform 89Zr-pembrolizumab-PET scan prior treatment pembrolizumab , uptake tracer tumor lesion normal organ distribution evaluate , could lead new insight heterogeneity PD-1 expression , well use 89Zr-pembrolizumab-PET complementary tool patient selection future . Objective : Primary objective : To evaluate whole body distribution 89Zr-pembrolizumab patient locally advance metastatic melanoma NSCLC . Secondary objective : ) To evaluate pharmacokinetics 89Zr-pembrolizumab ; ii ) To assess heterogeneity 89Zr-pembrolizumab tumor uptake ; iii ) To describe safety 89Zr-pembrolizumab ; iv ) To correlate tumor response pembrolizumab , measure objective response rate ( ORR ) accord standard RECIST v1.1 assess investigator , specific tumor tracer uptake . Study design : This two center , single arm , investigator sponsor trail ( IST ) PET tracer 89Zr-pembrolizumab evaluate vivo whole body distribution 89Zr-pembrolizumab registered indication locally advance metastatic melanoma NSCLC Pembrolizumab treatment . Study population : Eligible patient locally advance metastatic melanoma NSCLC , eligible receive Pembrolizumab treatment least one tumor site accessible tumor biopsy . Intervention : In part A imaging trial , dose find image study perform assess optimal tracer protein dose 89Zr-pembrolizumab optimal interval tracer injection scan . Approximately 3 cohort 2-3 patient undergo 89Zr-pembrolizumab-PET image start treatment pembrolizumab . In part B , 12 eligible patient undergo 89Zr-pembrolizumab-PET imaging baseline , optimal tracer protein dose scan schedule determine part A . In total , maximum 21 patient included.The purpose part B study analyze whole body distribution pharmacokinetics ( PK ) 89Zr-Pembrolizumab . Tumor normal organ radioactive tracer uptake quantify standardized uptake value ( SUV ) . Tumor biopsy collect baseline study various characteristic include Programmed cell death-ligand 1 ( PDL-1 ) , PD-1 expression tumor infiltrate lymphocyte . Pembrolizumab treatment administer standard care Main study parameters/endpoints : To evaluate whole body distribution 89Zr-pembrolizumab patient locally advance metastatic melanoma . Nature extent burden risk associate participation , benefit group relatedness : For image study patient make maximal 6 extra visit clinic screening , receive tracer injection maximal 3 PET/CT scan biopsy start standard treatment pembrolizumab . The study end last imaging biopsy ( whichever come first ) approximately take 7 day . Whenever possible , procedure part study protocol plan regular visit hospital part care usual . 89Zr-pembrolizumab-PET/CT implement radiation burden 20 millisievert ( mSv ) , 1.5 mSv per low-dose CT scan . Besides PET imaging , patient ask give total 12 blood sample ( 85 mL ) , give minor discomfort . A metastasis biopsy perform , preferably easily accessible lesion minimize burden risk patient . Based literature review , risk tumor biopsy consider low small risk significant/major complication death . The risk associate 89Zr-pembrolizumab seem minor although patient directly benefit study , result study valuable understanding tumor immune response guide prospective research .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Age ≥18 year . 2 . Histologically cytologically document locally advanced metastatic melanoma NSCLC . 3 . Patients must eligible treatment Pembrolizumab . For patient NSCLC include PDL1 expression ( &gt; 1 % base IHC assay ) tumor material . 4 . Metastatic lesion ( ) ( ≥1,0 cm ) histological biopsy safely obtain accord standard clinical care procedure . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Life expectancy ≥ 12 week . 7 . Signed Informed Consent Form . 8 . Ability comply protocol . 9 . Measurable disease , define standard RECIST v1.1 . Previously irradiated lesion count target lesion . 10 . Adequate hematologic end organ function , define follow laboratory result obtain within ≤ 14 day prior 89Zrpembrolizumab injection : Absolute Neutrophil Count ( ANC ) ≥ 1500 cells/μL ( without granulocyte colonystimulating factor support within 2 week prior 89Zrpembrolizumab injection ) White Blood Count ( WBC ) ≥ 2500/μL Lymphocyte count ≥ 500/μL Platelet count ≥ 100,000/μL ( without transfusion within 2 week prior 89ZrPembrolizumab injection ) Hemoglobin ≥9.0 g/dL . Patients may transfuse receive erythropoietin treatment meet criterion . Asparate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , alkaline phosphatase ≤2.5 x Upper Limit Normal ( ULN ) , follow exception : Patients document liver metastasis : AST and/or ALT ≤ 5 x ULN Patients document liver bone metastasis : alkaline phosphatase ≤ 5 x ULN Serum bilirubin ≤ 1.5 x ULN . Patients know Gilbert disease serum bilirubin level ≤3 x ULN may enrol . International Normalized Ratio ( INR ) Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 x ULN . This apply patient receive therapeutic anticoagulation ; patient receive therapeutic anticoagulation stable dose . Creatinine clearance ≥30 mL/min 11 . For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use highly effective form ( ) contraception ( i.e. , one result low failure rate [ &lt; 1 % per year ] use consistently correctly ) . 1 . Any approved anticancer therapy , include chemotherapy hormonal therapy within ≤14 day prior 89Zrpembrolizumab injection ; follow exception allow : • Hormonereplacement therapy oral contraceptive . 2 . Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior 89Zrpembrolizumab injection . 3 . Malignancies melanoma NSCLC within 5 year prior 89Zrpembrolizumab injection , exception negligible risk metastasis death treat expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat curative intent ductal carcinoma situ treat surgically curative intent ) . 4 . Pregnant lactating woman . 5 . Symptomatic brain metastasis . 6 . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . 7 . Known hypersensitivity allergy component pembrolizumab formulation . 8 . History autoimmune disease , include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis . Patients history autoimmunerelated hypothyroidism stable dose thyroid replacement hormone may eligible study . Patients control Type I diabetes mellitus stable dose insulin regimen may eligible study . 9 . Positive test Human Immunodeficiency Virus ( HIV ) . 10 . Patients active hepatitis B ( chronic acute ; define positive hepatitis B surface antigen [ HBsAg ] test screening ) hepatitis C. Patients past hepatitis B virus ( HBV ) infection resolve HBV infection ( define presence hepatitis B core antibody [ HBcAb ] absence HBsAg ) eligible . HBV DNA test must perform patient prior 89ZrPembrolizumab injection . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction negative HCV RNA . 11 . Signs symptoms infection within 2 week prior 89Zrpembrolizumab injection . 12 . Major surgical procedure diagnosis within 28 day prior 89Zrpembrolizumab injection anticipation need major surgical procedure course study . 13 . Prior allogeneic bone marrow transplantation solid organ transplant . 14 . Treatment corticosteroid increase dosage 7 day prior 89Zrpembrolizumab injection . ( A stable decreasing dosage ≤ 1,5 mg dexamethasone ≤ 10 mg prednisolone equivalent allow . In addition , inhaled topical steroid adrenal replacement dos permit absence active autoimmune disease . ) 15 . Inability comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pembrolizumab</keyword>
	<keyword>PET image</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>